Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G17DT in metastatic colorectal cancer
NCT02228785Phase 2Terminated
- Sponsor
- Cancer Advances, Inc.
- Start
- May 1994
- Primary completion
- Oct 1994
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of G17DT immunogen in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Cancer Advances, Inc. Primary endpoints: Injection Site Reaction and Antibody Levels. Started May 1994; status: terminated.
02
Drugs
G17DT immunogen
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02228785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228785.